We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current DNPUF market cap is 1.51B. The company's latest EPS is JPY -792.7874 and P/E is 0.00.
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 483.82B | 516.69B | 562.17B | 572.09B | 316.14B |
| Operating Income | 82.92B | 54.3B | 59.97B | -113.69B | -354.64B |
| Net Income | 35.92B | 56.22B | 56.41B | -74.51B | -314.97B |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 1.25T | 1.31T | 1.31T | 1.13T | 907.51B |
| Total Liabilities | 620.77B | 659.95B | 634.44B | 727.96B | 751.37B |
| Total Equity | 632.11B | 648.18B | 673.57B | 406.78B | 156.14B |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 46.13B | 135.6B | 31.24B | 11.94B | -241.89B |
| Investing | -312.68B | 8.88B | -18.28B | 52.42B | 33.04B |
| Financing | 231.08B | -57.22B | -21.43B | -146.82B | 77.85B |
| Market Cap | 1.51B |
| Price to Earnings Ratio | 0.00 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.05 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | - |
| Shares Outstanding | 397.29M |
| Average Volume (1 week) | 1.23k |
| Average Volume (1 Month) | 1.23k |
| 52 Week Change | 19.12% |
| 52 Week High | 4.50 |
| 52 Week Low | 1.99 |
| Spread (Intraday) | 0.83 (19.04%) |
| Company Name | Dai Nippon Pharmaceutical (PK) |
| Address |
2-6-8 doshomachi osaka, osaka 541-0045 |
| Website | https://www.ds-pharma.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
